Skip to main content
Top
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Cervical Cancer | Primary research

The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer

Authors: Hui Jiang, Min liang, Yanqiong Jiang, Ting Zhang, Kexin Mo, Suwen Su, Aiping Wang, Yongyi Zhu, Guanqun Huang, Rujian Zhou

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Recently, lncRNA-Testis developmental related gene 1 (TDRG1) was proved to be a key modulator in reproductive organ-related cancers. The biological role of TDRG1 in cervical cancer (CC) progression remains largely unknown.

Method

Real-time PCR (qRT-PCR) examined the expression level of TDRG1, microRNA (miR)-326 and MAPK1 mRNA. OS tissues and corresponding relative normal tissues, as well as CC cell lines and normal cell line Ect1/E6E7 were collected to determine the expression of TDRG1 in CC. MTT, colony formation, wound-healing, transwell and flow cytometer assay detected the influence of TDRG1 and miR-326 on CC cells growth, metastasis and apoptosis. Western blot examined proteins level. Bioinformatics, RNA pull-down assay, RNA immunoprecipitation and dual-luciferase reporter assays detected the molecular mechanism of TDRG1 in CC. Xenograft tumour model was established to determine the role of TDRG1 in vivo.

Results

The expression of TDRG1 was significantly increased in CC tissues and cell lines compared with normal tissue and normal cell line respectively and its expression was associated with clinicopathological characteristics of CC patients. Knockdown of TDRG1 inhibited the cell proliferation, migration and invasion in Hela and SIHA cells. Moreover, TDRG1 directly interacted with miR-326, and the inhibition effect on cell growth and metastasis induced by TDRG1 siRNA can be abrogated by miR-326 silencing by its inhibitor in Hela and SIHA cells. Further, MAPK1 was proved to be a direct target of miR-326, and its expression was negatively regulated by miR-326 while positively modulated by TDRG1.

Conclusion

TDRG1 acts as a competing endogenous lncRNA (ceRNA) to modulate MAPK1 by sponging miR-326 in CC, shedding new light on TDRG1-directed diagnostics and therapeutics in CC.
Literature
1.
go back to reference Morris E, Roett MA. Genital cancers in women: cervical cancer. FP Essent. 2015;438:18–23.PubMed Morris E, Roett MA. Genital cancers in women: cervical cancer. FP Essent. 2015;438:18–23.PubMed
2.
go back to reference Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol. 2016;28:4–10.CrossRef Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol. 2016;28:4–10.CrossRef
3.
go back to reference Lahue BJ, Baginska E, Li SS, et al. Health technology assessment on cervical cancer screening, 2000–2014. Int J Technol Assess Health Care. 2015;31:171–80.CrossRef Lahue BJ, Baginska E, Li SS, et al. Health technology assessment on cervical cancer screening, 2000–2014. Int J Technol Assess Health Care. 2015;31:171–80.CrossRef
4.
go back to reference Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer. 2018;42(5):457–65.CrossRef Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer. 2018;42(5):457–65.CrossRef
5.
go back to reference Yee GP, de Souza P, Khachigian LM. Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 2013;13:205–20.CrossRef Yee GP, de Souza P, Khachigian LM. Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 2013;13:205–20.CrossRef
6.
go back to reference Dong J, Su M, Chang W, et al. Long non-coding rnas on the stage of cervical cancer (review). Oncol Rep. 2017;38:1923–31.CrossRef Dong J, Su M, Chang W, et al. Long non-coding rnas on the stage of cervical cancer (review). Oncol Rep. 2017;38:1923–31.CrossRef
7.
go back to reference Han Li C, Chen Y. Small and long non-coding rnas: novel targets in perspective cancer therapy. Curr Genomics. 2015;16:319–26.CrossRef Han Li C, Chen Y. Small and long non-coding rnas: novel targets in perspective cancer therapy. Curr Genomics. 2015;16:319–26.CrossRef
8.
go back to reference Jiang X, Li D, Yang J, et al. Characterization of a novel human testis-specific gene: testis developmental related gene 1 (tdrg1). Tohoku J Exp Med. 2011;225:311–8.CrossRef Jiang X, Li D, Yang J, et al. Characterization of a novel human testis-specific gene: testis developmental related gene 1 (tdrg1). Tohoku J Exp Med. 2011;225:311–8.CrossRef
9.
go back to reference Chen H, Sun J, He Y, et al. Expression and localization of testis developmental related gene 1 (tdrg1) in human spermatozoa. Tohoku J Exp Med. 2015;235:103–9.CrossRef Chen H, Sun J, He Y, et al. Expression and localization of testis developmental related gene 1 (tdrg1) in human spermatozoa. Tohoku J Exp Med. 2015;235:103–9.CrossRef
10.
go back to reference Gan YU, Yang J, Wang Y, et al. In vitro study on shrna-mediated reduction of testis developmental related gene 1 expression and its effects on the proliferation, invasion and apoptosis of ntera-2 cells. Oncol Lett. 2015;10:61–6.CrossRef Gan YU, Yang J, Wang Y, et al. In vitro study on shrna-mediated reduction of testis developmental related gene 1 expression and its effects on the proliferation, invasion and apoptosis of ntera-2 cells. Oncol Lett. 2015;10:61–6.CrossRef
11.
go back to reference Chen S, Wang LL, Sun KX, et al. The role of the long non-coding rna tdrg1 in epithelial ovarian carcinoma tumorigenesis and progression through mir-93/rhoc pathway. Mol Carcinog. 2018;57:225–34.CrossRef Chen S, Wang LL, Sun KX, et al. The role of the long non-coding rna tdrg1 in epithelial ovarian carcinoma tumorigenesis and progression through mir-93/rhoc pathway. Mol Carcinog. 2018;57:225–34.CrossRef
12.
go back to reference Chen S, Wang LL, Sun KX, et al. Lncrna tdrg1 enhances tumorigenicity in endometrial carcinoma by binding and targeting vegf-a protein. Biochim Biophys Acta. 1864;2018:3013–21. Chen S, Wang LL, Sun KX, et al. Lncrna tdrg1 enhances tumorigenicity in endometrial carcinoma by binding and targeting vegf-a protein. Biochim Biophys Acta. 1864;2018:3013–21.
13.
go back to reference Salmena L, Poliseno L, Tay Y, et al. A cerna hypothesis: the rosetta stone of a hidden rna language? Cell. 2011;146:353–8.CrossRef Salmena L, Poliseno L, Tay Y, et al. A cerna hypothesis: the rosetta stone of a hidden rna language? Cell. 2011;146:353–8.CrossRef
14.
go back to reference Adams BD, Parsons C, Walker L, et al. Targeting noncoding rnas in disease. J Clin Invest. 2017;127:761–71.CrossRef Adams BD, Parsons C, Walker L, et al. Targeting noncoding rnas in disease. J Clin Invest. 2017;127:761–71.CrossRef
15.
go back to reference Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed rnas. Science. 2001;294:853–8.CrossRef Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed rnas. Science. 2001;294:853–8.CrossRef
16.
go back to reference Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRef Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRef
17.
go back to reference Chan JJ, Tay Y. Noncoding rna: Rna regulatory networks in cancer. Int J Mol Sci. 2018;19(5):E1310.CrossRef Chan JJ, Tay Y. Noncoding rna: Rna regulatory networks in cancer. Int J Mol Sci. 2018;19(5):E1310.CrossRef
18.
go back to reference Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding rnas in cancer. Biochem J. 2017;474:4219–51.CrossRef Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding rnas in cancer. Biochem J. 2017;474:4219–51.CrossRef
19.
go back to reference Zhang P, Kong F, Deng X, et al. MicroRNA-326 suppresses the proliferation, migration and invasion of cervical cancer cells by targeting elk1. Oncol Lett. 2017;13:2949–56.CrossRef Zhang P, Kong F, Deng X, et al. MicroRNA-326 suppresses the proliferation, migration and invasion of cervical cancer cells by targeting elk1. Oncol Lett. 2017;13:2949–56.CrossRef
21.
go back to reference Cheng Y, Jiang S, Yuan J, et al. Vascular endothelial growth factor c promotes cervical cancer cell invasiveness via regulation of microRNA-326/cortactin expression. Gynecol Endocrinol. 2018;34(10):853–8.CrossRef Cheng Y, Jiang S, Yuan J, et al. Vascular endothelial growth factor c promotes cervical cancer cell invasiveness via regulation of microRNA-326/cortactin expression. Gynecol Endocrinol. 2018;34(10):853–8.CrossRef
23.
go back to reference Jung YC, Han S, Hua L, et al. Kazinol-e is a specific inhibitor of erk that suppresses the enrichment of a breast cancer stem-like cell population. Biochem Biophys Res Commun. 2016;470:294–9.CrossRef Jung YC, Han S, Hua L, et al. Kazinol-e is a specific inhibitor of erk that suppresses the enrichment of a breast cancer stem-like cell population. Biochem Biophys Res Commun. 2016;470:294–9.CrossRef
24.
go back to reference Bai J, Zheng Y, Wang G, et al. Protective effect of d-limonene against oxidative stress-induced cell damage in human lens epithelial cells via the p38 pathway. Oxid Med Cell Longev. 2016;2016:5962832.PubMed Bai J, Zheng Y, Wang G, et al. Protective effect of d-limonene against oxidative stress-induced cell damage in human lens epithelial cells via the p38 pathway. Oxid Med Cell Longev. 2016;2016:5962832.PubMed
25.
go back to reference Li XW, Tuergan M, Abulizi G. Expression of mapk1 in cervical cancer and effect of mapk1 gene silencing on epithelial-mesenchymal transition, invasion and metastasis. Asian Pac J Trop Med. 2015;8:937–43.CrossRef Li XW, Tuergan M, Abulizi G. Expression of mapk1 in cervical cancer and effect of mapk1 gene silencing on epithelial-mesenchymal transition, invasion and metastasis. Asian Pac J Trop Med. 2015;8:937–43.CrossRef
26.
go back to reference Blain SW. Switching cyclin d-cdk4 kinase activity on and off. Cell Cycle. 2008;7:892–8.CrossRef Blain SW. Switching cyclin d-cdk4 kinase activity on and off. Cell Cycle. 2008;7:892–8.CrossRef
27.
go back to reference Niu L, Liu A, Xu W, et al. Downregulation of peroxiredoxin ii suppresses the proliferation and metastasis of gastric cancer cells. Oncol Lett. 2018;16:4551–60.PubMedPubMedCentral Niu L, Liu A, Xu W, et al. Downregulation of peroxiredoxin ii suppresses the proliferation and metastasis of gastric cancer cells. Oncol Lett. 2018;16:4551–60.PubMedPubMedCentral
28.
go back to reference Smith RA, Brooks D, Cokkinides V, Cancer screening in the united states, et al. A review of current american cancer society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2013):88–105.PubMed Smith RA, Brooks D, Cokkinides V, Cancer screening in the united states, et al. A review of current american cancer society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2013):88–105.PubMed
29.
go back to reference Kim JJ, Campos NG, Syss S, et al. Inefficiencies and high-value improvements in U.S. Cervical cancer screening practice: a cost-effectiveness analysis. Ann Intern Med. 2015;163:589–97.CrossRef Kim JJ, Campos NG, Syss S, et al. Inefficiencies and high-value improvements in U.S. Cervical cancer screening practice: a cost-effectiveness analysis. Ann Intern Med. 2015;163:589–97.CrossRef
30.
go back to reference Hosseini ES, Meryet-Figuiere M, Sabzalipoor H, et al. Dysregulated expression of long noncoding rnas in gynecologic cancers. Mol Cancer. 2017;16:107.CrossRef Hosseini ES, Meryet-Figuiere M, Sabzalipoor H, et al. Dysregulated expression of long noncoding rnas in gynecologic cancers. Mol Cancer. 2017;16:107.CrossRef
31.
go back to reference Aalijahan H, Ghorbian S. Long non-coding rnas and cervical cancer. Exp Mol Pathol. 2019;106:7–16.CrossRef Aalijahan H, Ghorbian S. Long non-coding rnas and cervical cancer. Exp Mol Pathol. 2019;106:7–16.CrossRef
32.
go back to reference Wang Y, Gan Y, Tan Z, et al. Tdrg1 functions in testicular seminoma are dependent on the pi3k/akt/mtor signaling pathway. Onco Targets Ther. 2016;9:409–20.PubMedPubMedCentral Wang Y, Gan Y, Tan Z, et al. Tdrg1 functions in testicular seminoma are dependent on the pi3k/akt/mtor signaling pathway. Onco Targets Ther. 2016;9:409–20.PubMedPubMedCentral
33.
go back to reference Gan Y, Wang Y, Tan Z, et al. Tdrg1 regulates chemosensitivity of seminoma tcam-2 cells to cisplatin via pi3 k/akt/mtor signaling pathway and mitochondria-mediated apoptotic pathway. Cancer Biol Ther. 2016;17:741–50.CrossRef Gan Y, Wang Y, Tan Z, et al. Tdrg1 regulates chemosensitivity of seminoma tcam-2 cells to cisplatin via pi3 k/akt/mtor signaling pathway and mitochondria-mediated apoptotic pathway. Cancer Biol Ther. 2016;17:741–50.CrossRef
34.
go back to reference Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of cerna crosstalk and competition. Nature. 2014;505:344–52.CrossRef Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of cerna crosstalk and competition. Nature. 2014;505:344–52.CrossRef
35.
go back to reference Ghodousi ES, Rahgozar S. MicroRNA-326 and microRNA-200c: two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. J Cell Biochem. 2018;119:6024–32.CrossRef Ghodousi ES, Rahgozar S. MicroRNA-326 and microRNA-200c: two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. J Cell Biochem. 2018;119:6024–32.CrossRef
36.
go back to reference Kang K, Zhang J, Zhang X, et al. MicroRNA-326 inhibits melanoma progression by targeting kras and suppressing the akt and erk signalling pathways. Oncol Rep. 2018;39:401–10.PubMed Kang K, Zhang J, Zhang X, et al. MicroRNA-326 inhibits melanoma progression by targeting kras and suppressing the akt and erk signalling pathways. Oncol Rep. 2018;39:401–10.PubMed
37.
go back to reference Yu G, Sun W, Shen Y, et al. Pkm2 functions as a potential oncogene and is a crucial target of mir-148a and mir-326 in thyroid tumorigenesis. Am J Transl Res. 2018;10:1793–801.PubMedPubMedCentral Yu G, Sun W, Shen Y, et al. Pkm2 functions as a potential oncogene and is a crucial target of mir-148a and mir-326 in thyroid tumorigenesis. Am J Transl Res. 2018;10:1793–801.PubMedPubMedCentral
38.
go back to reference Xu MJ, Johnson DE, Grandis JR. Egfr-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017;36:463–73.CrossRef Xu MJ, Johnson DE, Grandis JR. Egfr-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017;36:463–73.CrossRef
39.
go back to reference Li W, Liang J, Zhang Z, et al. MicroRNA-329-3p targets mapk1 to suppress cell proliferation, migration and invasion in cervical cancer. Oncol Rep. 2017;37:2743–50.CrossRef Li W, Liang J, Zhang Z, et al. MicroRNA-329-3p targets mapk1 to suppress cell proliferation, migration and invasion in cervical cancer. Oncol Rep. 2017;37:2743–50.CrossRef
40.
go back to reference Li Q, Feng Y, Chao X, et al. Hotair contributes to cell proliferation and metastasis of cervical cancer via targetting mir-23b/mapk1 axis. Biosci Rep. 2018;38:BSR20171563.CrossRef Li Q, Feng Y, Chao X, et al. Hotair contributes to cell proliferation and metastasis of cervical cancer via targetting mir-23b/mapk1 axis. Biosci Rep. 2018;38:BSR20171563.CrossRef
Metadata
Title
The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer
Authors
Hui Jiang
Min liang
Yanqiong Jiang
Ting Zhang
Kexin Mo
Suwen Su
Aiping Wang
Yongyi Zhu
Guanqun Huang
Rujian Zhou
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0872-4

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine